| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetrics Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 3369 | Michael Ward | National Institutes of Health (NIH) | Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis | Wang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022;5(3):e222312. doi: 10.1001/jamanetworkopen.2022.2312 | AbbVie, Pfizer | 20 | |
| 4115 | Amir Mahabadi | University Hospital Essen, West German Heart and Vascular Center | Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trials | L Vogel, I Dykun, P Raggi, A Schmermund, T Rassaf, A Mahabadi. High- vs. low-intensity statin therapy and changes in coronary artery calcification density after one year. European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.209. doi: 10.1093/eurheartj/ehac544.209 | Pfizer | N/A | |
| 4116 | Sharon Strauss | St. Michael’s Hospital | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis | Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis BMJ Open 2022;12:e053012. doi: 10.1136/bmjopen-2021-053012 | AbbVie | 50 | |
| 4120 | Merryn Voysey | University of Oxford | The immunogenicity and sero-efficacy of pneumococcal vaccines | Shuo Feng, Julian Higgins, Maria Knoll, Julie Mclellan, Kim Muholland, Nicola Pidduck, Andrew Pollard, Beth Temple, Merryn Voysey. COMPARISON OF IMMUNOGENICITY AND SEROEFFICACY BETWEEN TEN- AND THIRTEEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINES – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. | Pfizer | N/A | N/A |
| 4316 | Martin Okun | Fort Healthcare | Geospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis. | Okun TSD, Okun MM. No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated. Journal of Psoriasis and Psoriatic Arthritis. January 2022. doi: 10.1177/24755303221079810 | AbbVie | N/A | |
| 4326 | John Markman | University of Rochester | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | Gewandter JS, Sohn MB, De Guzman R, Frazer ME, Chiodo V, Sharma S, Geha P, Markman JD. Predicting treatment response with sensory phenotyping in post-traumatic neuropathic pain. Pain Med. 2022 Mar 21:pnac045. PMID: 35312012. doi: 10.1093/pm/pnac045 | Pfizer | 2 | |
| 4326 | John Markman | University of Rochester | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | Olaposi Peters, John Markman, Michael Sohn, Rachel De Guzman, Maria Frazer, Valerie Chiodo, Sonia Sharma, Paul Geha, Jennifer Gewandter. Predicting treatment response with sensory phenotyping in posttraumatic neuropathic pain. CPS 2022 Book of Abstracts Final, page 277. | Pfizer | N/A | N/A |
| 4329 | Shomron Ben-Horin | Sun Yatsen 1st affiliated Hospital | Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease | Shomron Ben-Horin, Lena Novack, Ren Mao, Jing Guo, Yue Zhao, Ruslan Sergienko, Jian Zhang, Taku Kobayashi, Toshifumi Hibi, Yehuda Chowers, Laurent Peyrin-Biroulet, Jean Frederic Colombel, Gilaad G. Kaplan, Min-hu Chen. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology, 2021, ISSN 0016-5085. doi: 10.1053/j.gastro.2021.10.037 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | 48 | |
| 4921 | Tim Brümmendorf | University Hospital Aachen | Entropy-based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML | Esfahani, Ali, Susanne Isfort, Tim Brümmendorf, and Andreas Schuppert. Entropy-based Biomarkers for Individualized Response on Bosutinib Treatment in Chronic Phase CML. OSF Preprints. March 1, 2022. doi:10.31219/osf.io/bu2qy | Pfizer | N/A | |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Takase-Minegishi K, Böhringer S, Nam J, Kaneko Y, Behrens F, Saevarsdottir S, Detert J, Leirisalo-Repo M, van der Heijde D, Landewé R, Ramiro S, van der Woude D. The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). http://bit.ly/47kyLsM | AbbVie, Pfizer | N/A | N/A |
| 5086 | Junko Takeshita | University of Pennsylvania | A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases | Sevagamoorthy A, Sockler P, Akoh C, Takeshita J. Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review. J Dermatolog Treat. 2022 Aug 31:1-12 doi : 10.1080/09546634.2022.2114783 | AbbVie, Lilly, Regeneron | 10 | |
| 5163 | Susan Bates | Columbia University Medical Center | Assessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data | Celine Yeh, Mengxi Zhou, Keith Sigel, Gayle Jameson, Ruth White, Rachael Safyan, Yvonne Saenger, Elizabeth Hecht, John Chabot, Stephen Schreibman, Béata Juzyna, Marc Ychou, Thierry Conroy, Tito Fojo, Gulam A Manji, Daniel Von Hoff, Susan E Bates. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. The Oncologist, 2022. doi : 10.1093/oncolo/oyac217 | Bristol Myers Squibb | 3 | |
| 5165 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat | Ghang B, Lee JS, Choi J, et al. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open 2022;8:e001944 doi: 10.1136/rmdopen-2021-001944 | Takeda | 8 | |
| 5207 | Fasihul Khan | University of Nottingham | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | Khan FA, Stewart I, Moss S, Fabbri L, Robinson KA, Johnson SR, Jenkins RG. Three-Month FVC Change: A Trial Endpoint for IPF Based on Individual Participant Data Meta-Analysis. Am J Respir Crit Care Med. 2022 Jan 12. doi: 10.1164/rccm.202109-2091OC | BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche | 11 | |
| 5291 | Sarah Nevitt | University of Liverpool | Antiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis | Nevitt SJ, Sudell M, Cividini S, Marson AG, Tudur Smith C. Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No.: CD011412. doi: 10.1002/14651858.CD011412.pub4 | UCB | 44 | |
| 5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach | Duong, S.Q., Crowson, C.S., Athreya, A., Atkinson, E.J., Davis, J.M., Warrington, K.J., Matteson, E.L., Weinshilboum, R., Wang, L. and Myasoedova, E. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. Arthritis Res Ther 24, 162 (2022). doi: 10.1186/s13075-022-02851-5 | Roche, UCB | 27 | |
| 5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach | Duong S, Crowson CS, Athreya A, et al. POS0514 PREDICTION OF RESPONSE TO METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A MACHINE LEARNING APPROACH USING CLINICAL TRIAL DATA. Annals of the Rheumatic Diseases 2022;81:513-514. doi:10.1136/annrheumdis-2022-eular.891 | Roche, UCB | N/A | |
| 5456 | Terina Martinez | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | R. Belfiore-Oshan, V. Aggarwal, S. Sivakumaran, D. Corey, C. Ollivier, K. Romero, K. Vandenborne, S. Kim, J. Morales, K. Lingineni, T. Martinez. VP.85. C-Path's Duchenne Regulatory Science Consortium: Accelerating drug development for Duchenne muscular dystrophy. Neuromuscular Disorders, Volume 32, Supplement 1. 2022. Page S128. doi: 10.1016/j.nmd.2022.07.359 | CureDuchenne | N/A | N/A |
| 5456 | Terina Martinez | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Varun Aggarwal, Rhoda Muse, Sarah Kim, Jackson Burton, Diane Corey, Lauren Quinlan, Klaus Romero, Ramona Belfiore-Oshan, Terina Martinez. Multivariate Joint Models to Predict Clinically Meaningful Decline in Duchenne Muscular Dystrophy as measured by NSAA Using Timed Function Test Trajectories. ACoP13 (2022) STPM-328. | CureDuchenne | N/A | N/A |
| 5812 | Yougen Wu | The Fifth People's Hospital of Shanghai, Fudan University | Development and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors | Wu Y, Zhu W, Wang J, Liu L, Zhang W, Wang Y, Shi J, Xia J, Gu Y, Qian Q, Hong Y. Using machine learning for mortality prediction and risk stratification in atezolizumab-treated cancer patients: Integrative analysis of eight clinical trials. Cancer Med. 2022 Jul 24. doi: 10.1002/cam4.5060 | Roche | 8 | |
| 5853 | Florian Naudet | CHU Rennes | Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment Reports | Siebert, M., Gaba, J., Renault, A. et al. Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports. BMC Med 20, 177 (2022). doi:10.1186/s12916-022-02377-2 | AbbVie | 4 | |
| 5869 | Alexandra Freeman | University of Cambridge | Meta-analysis of the adverse effects of trastuzumab in women with breast cancer | Jackson, C., Finikarides, L. and Freeman, A., 2022. The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: a piggy-back systematic review and meta-analysis. doi: 10.1371/journal.pone.0275321 | Roche | 10 | |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Eugene Tan, Ahmad Y. Abuhelwa, Sarah Badaoui, Natansh D. Modi, Michael D. Wiese, Ross A. McKinnon, Michael J. Sorich and Ashley M. Hopkins. Association Between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. 1 Jan, 2021 : 1 doi: 10.3233/BLC-211613 | Roche | 6 | |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Badaoui S, Shahnam A, McKinnon RA, Abuhelwa AY, Sorich MJ, Hopkins AM. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy. Transl Lung Cancer Res 2022;11(3):432-439. doi: 10.21037/tlcr-21-9385 | Roche | 16 | |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Hopkins, A. M., Badaoui, S., Kichenadasse, G., Karapetis, C. S., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2022). Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials. Journal of Thoracic Oncology. doi: https://doi.org/10.1016/j.jtho.2022.02.003 | Roche | 24 | |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Abuhelwa AY, Bellmunt J, Kichenadasse G, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM. C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab. Front Oncol. 2022 Aug 1;12:918993. doi: 10.3389/fonc.2022.918993 | Roche | 4 | |
| 5902 | Thrasyvoulos Tzellos | Norland University Hospital | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | Thrasivoulos Tzellos Et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2022 Oct 2. doi: 10.1111/jdv.18632. Online ahead of print. | AbbVie | 21 | |
| 5902 | Thrasyvoulos Tzellos | Norland University Hospital | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | K. R. van Straalen, T. Tzellos, A. Alavi, F. Benhadou, C. Cuenca-Barrales, M. Daxhelet, M. Daoud, O. Efthymiou, E. J. Giamarellos-Bourboulis, P. Guillem, W. Gulliver, G. B. Jemec, A. Katoulis, A. Koenig, E. Lazaridou, M. Lowes, A. V. Marzano, L. Matusiak, A. Molina-Leyva, C. Moltrasio, A. Pinter, C. Potenza, E. P. Prens, J. Romaní, D. M. Saunte, C. J. Sayed, N. Skroza, D. Stergianou, J. C. Szepietowski, A. Trigoni, E. Vilarrasa, H. H. van der Zee, A. Kyrgidis, C. C. Zouboulis. (2022), 11th EHSF Conference 2022 Abstracts. Exp Dermatol, 31: 40-125. S-01-12 – Development and validation of an IHS4 dichotomous outcome to assess treatment effect. (p.47). Doi: 10.11111/exd.14557 | AbbVie | 1 | |
| 5933 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Manning-Bennett, A. T., Hopkins, A. M., Sorich, M. J., Proudman, S. M., Foster, D. J. R., Abuhelwa, A. Y., & Wiese, M. D. (2022). The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis – a pooled analysis of five randomised controlled trials. Therapeutic Advances in Musculoskeletal Disease. doi:10.1177/1759720X221111613 | Roche | 15 | |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Daraghmeh DN, Hopkins AM, King C, Abuhelwa AY, Wechalekar MD, Proudman SM, Sorich MJ, Wiese MD. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford). 2022 Jun 22:keac357. doi : 10.1093/rheumatology/keac357 | Roche | 2 | |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Manning-Bennett A, Hopkins A, Sorich M, Proudman S, Foster D, Abuhelwa A, Wiese M. The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis [abstract]. Arthritis Rheumatol. 20 22; 74 (suppl 9). ACR Convergence 2022 abstract | Lilly | N/A | N/A |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou J, Yang J, Wang H, et al. Machine learning based on blood biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy. Annals of Oncology (2022) 33 (suppl_2): S27-S70. doi: 10.1016/j.annonc.2022.02.069 | Roche | N/A | N/A |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Ma, SC., Bai, X., Guo, XJ., Liu, L., Xiao, LS., Lin, Y., Tan, JL., Cai, XT., Wen, YX., Ma, H., Fu, QJ., Leng, MX., Zhang, YP., Long, LL., Guo, ZQ., Wu, DH., Zhou, JG., Dong, ZY. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC Med 20, 120 (2022). doi: 10.1186/s12916-022-02315-2 | Roche | 10 | |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Development and validation of longitudinal c-reactive protein as dynamic response predictor for PD-L1 blockade in advanced NSCLC: Findings from four atezolizumab clinical trials. Jian-Guo Zhou, Xiaofei Chen, Ada Hang-Heng Wong, Haitao Wang, Fangya Tan, Si-Si He, Gang Shen, YunJia Wang, Ruihong Wang, Shamus R. Carr, Benjamin Frey, Rainer Fietkau, Markus Hecht, Hu Ma, David S. Schrump, and Udo S Gaipl. Journal of Clinical Oncology 2022 40:16_suppl, e21113-e21113. doi: 10.1200/JCO.2022.40.16_suppl.e21113. | Roche | N/A | |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, J.G., Wong, A.H.H., Wang, H., Tan, F., Chen, X., Jin, S.H., He, S., Shen, G., Wang, Y.J., Frey, B. and Fietkau, R. Elucidation of the application of blood test biomarkers to predict immune-related adverse events (irAEs) in atezolizumab-treated NSCLC patients by using machine learning methods. Frontiers in Immunology, p.3081. doi: 10.3389/fimmu.2022.862752 | Roche | 12 | |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou J, Wong A, Wang H, Jin S, Tan F, Chen Y, He S, Shen G, Frey B, Fietkau R, Hecht M, Carr S, Wang R, Shen B, Schrump D, Ma H and Gaipl US(2022) Definition of a new blood cell count (BCT) score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials. Front. Immunol. 13:961926. doi:10.3389/fimmu.2022.961926 | Roche | 1 | |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, Jian-Guo and Yang, Jie and Wang, Haitao and Wong, Ada Hang-Heng and Tan, Fangya and Chen, Xiaofei and he, sisi and Shen, Gang and Wang, Yun-Jia and Frey, Benjamin and Fietkau, Rainer and Hecht, Markus and Zhong, Wen-Zhao and Ma, Hu and Gaipl, Udo. Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy. DOI : 10.2139/ssrn.4214527 | Roche | N/A | |
| 5945 | Neeraj Narula | McMaster University | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | Wong ECL, Dulai PS, Narula N. Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system" by Gui et al. Gut. 2022 Jun 7. gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661 | Takeda | 0 | |
| 5951, 4543 | Mathilde Nijkeuter | UMC Utrecht | Individualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism | de Winter, M.A., Uijl, A., Büller, H.R., Carrier, M., Cohen, A.T., Hansen, J.B., Kaasjager, K.H., Kakkar, L.A.K., Middeldorp, S., Raskob, G.E. and Sørensen, H.T., 2022. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis. Journal of Thrombosis and Haemostasis. doi: 10.1016/j.jtha.2022.11.013 | Daiichi Sankyo | N/A | N/A |
| 5959 | John Dennis | University of Exeter Medical School | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | Dennis, J.M., Young, K.G., McGovern, A.P., Mateen, B.A., Vollmer, S.J., Simpson, M.D., Henley, W.E., Holman, R.R., Sattar, N., Pearson, E.R. and Hattersley, A.T., 2022. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. The Lancet Digital Health, 4(12), pp.e873-e883. doi: 10.1016/S2589-7500(22)00174-1 | Boehringer Ingelheim | 20 | |
| 5984 | David Baker | Queen Mary University of London | Exploring possibilities to improve the risk benefit balance through analysis of the ocrelizumab phase II extension study | Baker, D., MacDougall, A., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2022). CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 57, 103448. doi: 10.1016/j.msard.2021.103448 | Roche | 15 | |
| 6004 | Lily Lim | University of Manitoba | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Lim LSH, Shobhan S, Lokku A, Ringold S, Pullenayegum E. Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trials. Pediatr Rheumatol Online J. 2022 Jul 30;20(1):57. doi: 10.1186/s12969-022-00719-1 | Roche | 1 | |
| 6004 | Lily Lim | University of Manitoba | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Lim, L. S. H., Lokku, A., Pullenayegum, E., & Ringold, S. Probability of Response in the First 16 Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials. Arthritis Care & Research. doi: 10.1002/acr.25003 | Roche | 2 | |
| 6006 | Nicholas White | Mahidol University | A Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19 | Chotsiri, P., Tarning, J., Hoglund, R.M., Watson, J. and White, N.J. (2022), Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. Clin Pharmacol Ther. doi:10.1002/cpt.2665 | Pfizer | 4 | |
| 6007 | Judith Goldstein | Johns Hopkins School of Medicine | National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD) | Judith E. Goldstein, Chris Bradley, Alden L. Gross, Marylou Jackson, Neil Bressler, Robert W. Massof; The NEI VFQ-25C: Calibrating Items in the National Eye Institute Visual Function Questionnaire-25 to Enable Comparison of Outcome Measures. Trans. Vis. Sci. Tech. 2022;11(5):10. doi: 10.1167/tvst.11.5.10. | Roche | 20 | |
| 6041 | Neeraj Narula | Hamilton Health Sciences | Histologic Predictors of Endoscopic Healing in Crohn's Disease | Emily C L Wong, BHSc, Arif Yusuf, MD, Jagoda Pokryszka, MD, Parambir S Dulai, MD, Jean-Frederic Colombel, MD, John K Marshall, MD, MSc, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease. Inflammatory Bowel Diseases. 2022, izac157. Original: https://doi.org/10.1093/ibd/izac157 Correction: https://doi.org/10.1093/ibd/izac208 | AbbVie | 2 | |
| 6062 | Alexander Meisel | University Hospital of Zurich | Neutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations | A. Meisel, M.T. Mark, A. Haider, L. Holer, S. Hayoz, C. Gebhard, S. Bengs, V. Treyer, S.I. Rothschild, M.J. Hochmair, D.R. Gandara, F. Cappuzzo, M. Reck, F. Stenner-Liewen, R.A.F. von Moos. 1051P - Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and hemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC). https://doi.org/10.1016/j.annonc.2022.07.1177 | Roche | N/A | N/A |
| 6494 | Maria Alice Franzoi | Jules Bordet Institute | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res Treat. 2022 Jan 25. doi: 10.1007/s10549-022-06525-3. | Lilly | 4 | |
| 6494 | Maria Alice Franzoi | Jules Bordet Institute | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Maria Alice Franzoi, Matteo Lambertini, Marcello Ceppi, Marco Bruzonne, Evandro de Azambuja. Abstract P5-13-07: Implications of body mass index (BMI) on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting. Cancer Res, 15 February 2022; 82 (4_Supplement): P5–13–07. doi: 10.1158/1538-7445.SABCS21-P5-13-07 | Lilly | N/A | |
| 6496 | Neeraj Narula | Hamilton Health Sciences | Endoscopic Disease Severity and Patient Reported Outcomes in Crohns Disease | Cara Pray, MD, Emily C L Wong, BHSc, Achuthan Aruljothy, MDCM, Parambir S Dulai, MD, John K Marshall, MD, MSc, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis. Inflammatory Bowel Diseases, 2022. izac210 doi : 10.1093/ibd/izac210 | AbbVie, Johnson & Johnson | 0 | |
| 6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer | N.D. Modi, N.O. Danell, R.N.A. Perry, A.Y. Abuhelwa, A. Rathod, S. Badaoui, R.A. McKinnon, M. Haseloff, A. Shahnam, S.M. Swain, M. Welslau, M.J. Sorich, A.M. Hopkins, "Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer", ESMO Open, Volume 7, Issue 3, 2022, 100475. doi:10.1016/j.esmoop.2022.100475 | Roche | 11 | |
| 6532 | Odelia Cooper | Cedars-Sinai Medical Center | A study of how growth hormone treatment affects health outcomes in patients with noncancerous craniopharyngioma tumors | Odelia Cooper, Sungjin Kim. ODP643 Metabolic Effects of Growth Hormone Replacement in Craniopharyngioma and Pituitary Adenoma Patients: Analysis of the Hypopituitary Control and Complications Study (HypoCCS) Database. Journal of the Endocrine Society, Volume 6, Issue Supplement_1, November-December 2022, Page A521. doi: 10.1210/jendso/bvac150.1085 | Lilly | N/A | |
| 6543 | Andreas Meid | Heidelberg University Hospital | Reproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) – can ML methods support the validity of conventional TGI metrics? | Meid, A., Gerharz, A., Groll, A. Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility. CPT: Pharmacometrics & Systems Pharmacology. 2022 Feb 01. doi: 10.1002/psp4.12761 | Roche | 3 | |
| 6601 | Dan Turner | Shaare Zedek Medical Center | Adaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial data | Dotan Yogev, MD, Bram Verstockt, MD, PhD, Axel Dignass, MD, PhD, Gili Focht, MSc, MBA, Ohad Atia, MD, Iris Dotan, MD, PhD, Severine Vermeire, MD, PhD, Dan Turner, MD, PhD. The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn’s Disease. Inflammatory Bowel Diseases, 2022;. izac235. doi : 10.1093/ibd/izac235 | AbbVie | 0 | |
| 6632 | Luca Valerio | University Medical Center of the Johannes Gutenberg-University Mainz | Healthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in venous thromboembolism (VTE) study | Farmakis IT, Barco S, Mavromanoli AC, Agnelli G, Cohen AT, Giannakoulas G, Mahan CE, Konstantinides SV, Valerio L. Cost-of-Illness Analysis of Long-Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry. J Am Heart Assoc. 2022 Oct 18;11(20):e027514. doi : 10.1161/JAHA.122.027514 | Daiichi Sankyo | 15 | |
| 6633 | Luca Valerio | University Medical Center Mainz | Performance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer study | Farmakis IT, Barco S, Mavromanoli AC, Konstantinides SV, Valerio L. Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism: Insights From the Hokusai-VTE Cancer Study. JACC CardioOncol. 2022 Nov 15;4(4):507-518. doi: 10.1016/j.jaccao.2022.07.008 | Daiichi Sankyo | 9 | |
| 6710 | Gus Slotman | Inspira Health Network | Identifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced Mortality | Kelter, David MD; Slotman, Gus J MD, FACS. Smart Identifies Dichotomous Drotrecogin Alfa Activated Treatment Effects on Mortality in Prowess Shock. Journal of the American College of Surgeons: November 2022 - Volume 235 - Issue 5 - p S296. doi: 10.1097/01.XCS.0000895332.83940.b8 | Lilly | N/A | |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Huang Y-C, Cheng Y-C, Jhou M-J, Chen M, Lu C-J. Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme—A Post Hoc Analysis. Journal of Personalized Medicine. 2022; 12(5):756. doi:10.3390/jpm12050756 | Boehringer Ingelheim | 9 | |
| 6734 | Andreas Suhrbier | QIMR Berghofer Medical Research Institute | The K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans | Bishop CR, Dumenil T, Rawle DJ, Le TT, Yan K, et al. Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. (2022). PLOS Pathogens 18(9): e1010867. Doi: 10.1371/journal.ppat.1010867 | Hannover Medical School | 19 | |
| 6765 | Dan Hanley | Johns Hopkins University | Pandemic response COVID-19 Research Collaboration Platform | Di Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, Baksh SN, McBee N, Gruber J, Gildea MR, Clark MR, Goldenberg NA, Bennani Y, Brown SM, Buckel WR, Clement ME, Mulligan MJ, O'Halloran JA, Rauseo AM, Self WH, Semler MW, Seto T, Stout JE, Ulrich RJ, Victory J, Bierer BE, Hanley DF, Freilich D. Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. PLoS One. 2022 Sep 29;17(9):e0273526. Doi: https://doi.org/10.1371/journal.pone.0273526 | NYU Grossman School of Medicine, Intermountain Healthcare, Washington University School of Medicine, Bassett Research Institute, The Queen's Medical Center, Duke University, University Medical Center New Orleans | 9 | |
| 6866 | Andy Lim | Monash University | Meta-analysis of early stroke recurrence rate in minor stroke | A. Lim, H. Ma, C. Johnson, S. Singhal, S. Muthusamy, Y. Wang, Y. Pan, S. Coutts, A. Ois, M.K Kapral, M. Knoflach, L.J Woodhouse, P.M Bath, T Phan. Ninety-day stroke recurrence rate in minor stroke: a meta-analysis of randomized trials and observational studies. European Stroke Journal. 2022;7(1_suppl):3-545. European Stroke Organisation Conference (ESOC) 2022 Abstract Book, O084 / 129 page 48. doi: 10.1177/23969873221087559. | AstraZeneca | N/A | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Ding, W.Y., Calvert, P., Gupta, D. et al. Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry. Clin Res Cardiol (2022). doi:10.1007/s00392-022-02022-1 | Boehringer Ingelheim | 8 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022 Aug 29. doi: 10.1055/s-0042-1756355 | Boehringer Ingelheim | 50 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Ding WY, Lane DA, Gupta D, Huisman MV, Lip GYH, GLORIA‐AF Investigators. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry. J Am Heart Assoc. 2022 Aug 2;11(15):e026410. doi : 10.1161/JAHA.122.026410. | Boehringer Ingelheim | 19 | |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | Wong, EC, Dulai, PS, Marshall, JK, Jairath, V, Reinisch, W, Narula, N. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease. Aliment Pharmacol Ther. 2022; 00: 1– 9. doi: 10.1111/apt.16805 | AbbVie, Johnson & Johnson | 3 | |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | N Narula, C Pray, E Wong, J F Colombel, J Marshall, M Daperno, W Reinisch, P Dulai. DOP16 Categorizing endoscopic severity of Crohn’s Disease using the Modified Multiplier SES-CD (MM-SES-CD). Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i065–i066. doi: 10.1093/ecco-jcc/jjab232.055 | AbbVie, Johnson & Johnson | N/A | |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | Neeraj Narula, Cara Pray, Emily C L Wong, Jean-Frederic Colombel, John K Marshall, Marco Daperno, Walter Reinisch, Parambir S Dulai. Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis, 2022;, jjac018,. doi: 10.1093/ecco-jcc/jjac018 | AbbVie, Johnson & Johnson | 6 | |
| 7126 | Alessio Cortellini | Imperial College London | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer | Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial. Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D'Alessio, Claudia A.M. Fulgenzi, Alfredo Addeo, Giuseppe Luigi L. Banna, and David J. James Pinato. Journal of Clinical Oncology 2022 40:16_suppl. https://doi.org/10.1200/JCO.2022.40.16_suppl.9056 | Roche | N/A | |
| 7126 | Alessio Cortellini | Imperial College London | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer | Cortellini, A., Ricciuti, B., Borghaei, H., Naqash, A.R., D'Alessio, A., Fulgenzi, C.A.M., Addeo, A., Banna, G.L. and Pinato, D.J. (2022), Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. doi: 10.1002/cncr.34348 | Roche | 20 | |
| 7158 | Neeraj Narula | Hamilton Health Sciences | Patient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis | Emily Chu Lee Wong, Badar Hasan, Parambir S. Dulai, John K. Marshall, Walter Reinisch & Neeraj Narula. (2022). End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis. Scandinavian Journal of Gastroenterology. DOI: 10.1080/00365521.2022.2105169 | Takeda | 1 | |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | Associations Between Steroid Treatment and Clinical Outcomes Among Non-ambulatory Patients with Duchenne Muscular Dystrophy (DMD) (P1-1.Virtual). Craig McDonald, Oscar Mayer, Kan Hor, Jessica Marden, Jonathan Freimark, Henry Lane, Adina Zhang, Molly Frean, Claudio Santos, Richard Able, James Signorovitch. Neurology May 2022, 98 (18 Supplement) 1348 https://doi.org/10.1212/WNL.98.18_supplement.1348 | CureDuchenne | N/A | N/A |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | Associations Between Deflazacort Versus Prednisone/Prednisolone and Markers of Disease Progression in Clinically Important Subgroups of Patients with Duchenne Muscular Dystrophy (P1-1.Virtual). Craig McDonald, Jessica Marden, Henry Lane, Adina Zhang, Ha Nguyen, Claudio Santos, Richard Able, James Signorovitch. Neurology May 2022, 98 (18 Supplement) 1437 https://doi.org/10.1212/WNL.98.18_supplement.1437 | CureDuchenne | N/A | N/A |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | McDonald CM, Mayer OH, Hor KN, Miller D, Goemans N, Henricson EK, Marden JR, Freimark J, Lane H, Zhang A, Frean M, Trifillis P, Koladicz K, Signorovitch J; PRO-DMD-01 consortium investigators. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2023;10(1):67-79. doi : 10.3233/JND-221575. | CureDuchenne | 7 | |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal J, Bald T, Hölzel M, Ritter M, Brossart P, Ellinger J, Klümper N. In the phase 3 IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. Ann Oncol. 2022 Jun 15:S0923-7534(22)01730-6. doi: 10.1016/j.annonc.2022.06.003 | Roche | 7 | |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal J, Bald T, Hölzel M, Ritter M, Brossart P, Ellinger J, Klümper N. P229 Der modifizierte Glasgow Prognostic Score (mGPS) sagt das Überleben in Patienten mit metastasiertem Nierenzellkarzinom in der Phase III IMmotion151 Studie besser voraus als der IMDC score. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022. Oncol Res Treat 27 September 2022; 45 (Suppl. 2): 5–346, Page 318. doi: 10.1159/000526456 | Roche | 0 | |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Narula, Neeraj MD, MPH, FRCPC; Wong, Emily C.L. BHSc; Marshall, John K. MD, MSc, FRCPC; Jairath, Vipul MD, PhD; Dulai, Parambir S. MD; Reinisch, Walter MD, PhD. Long-term Outcomes of Early Versus Delayed Responders to Vedolizumab and Adalimumab: A Post-hoc Analysis of VARSITY. The American Journal of Gastroenterology: September 1, 2022 - Volume - Issue - 10.14309/ajg.0000000000001987 doi : 10.14309/ajg.0000000000001987 | Takeda | 6 | |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Z. Alhashimalsayed, E. C.L. Wong, W. Reinisch, N. Narula. MP444 SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY. United European Gastroenterology Journal 2022; 10 (Supplement 8), October 2022. Moderated Posters p276/277. doi : 10.1002/ueg2.12294 | Takeda | N/A | |
| 7241 | Frederick Reimherr | Psychiatric and Behavioral Solutions, LLC | Retrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by Brexpiprazole | Reimherr, Frederick W.; Gift, Thomas E.; Steans, Tammy A.; Reimherr, Matthew L.; Rosenberg, Leon I.; Wilson, Melissa; Marchant, Barrie K. The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology: August 17, 2022 - Volume - Issue - 10.1097/JCP.0000000000001592. doi : 10.1097/JCP.0000000000001592. | Otsuka | 2 | |
| 7245 | Manabu Takaki | Okayama University | Clinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan | Nozomu Hashimoto, Hiroshi Habu, Soshi Takao, Shinji Sakamoto, Yuko Okahisa, Keitaro Matsuo, Manabu Takaki, Yoshiki Kishi, Norihito Yamada. Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: an exploratory analysis. Drug and Alcohol Dependence, 2022, 109365, ISSN 0376-8716. doi: 10.1016/j.drugalcdep.2022.109365 | Otsuka | 3 | |
| 7387 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease | Narula, Neeraj; Wong, Emily C.L.; Dulai, Parambir S.; Marshall, John K.; Jairath, Vipul; Reinisch, Walter. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease. The American Journal of Gastroenterology: April 15, 2022 - Volume - Issue - 10.14309/ajg.0000000000001795. doi: 10.14309/ajg.0000000000001795 | AbbVie, Johnson & Johnson, Takeda | 17 | |
| 7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Ghang B, Kim J, Yoo. BPOS0284 CHANGES OF ESTIMATED GLOMERULAR FILTRATION RATE AFTER LONG-TERM FEBUXOSTAT OR ALLOPURINOL TREATMENT IN GOUT PATIENTS. Annals of the Rheumatic Diseases 2022;81:386 . https://ard.bmj.com/content/81/Suppl_1/386.1.full | Takeda | N/A | |
| 7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Byeongzu Ghang, Jinseok Kim. Effects of long-term febuxostat or allopurinol on the progression of chronic kidney disease. Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022 p271 O-54. | Takeda | N/A | N/A |
| 7414 | Nobuyuki Horita | Yokohama City University Hospital | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis. | Horita, N. Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. Cancers 2023, 15, 185. doi: 10.3390/cancers15010185 | Roche | 0 | |
| 7414 | Nobuyuki Horita | Yokohama City University Hospital | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis. | Ayaka Maeda, Kaoru Takase-Minegishi, Yohei Kirino, Naoki Hamada, Yosuke Kunishita, Ryusuke Yoshimi, Akira Meguro, Ho Namkoong, Nobuyuki Horita, Hideaki Nakajima, Yokohama City University irAE Working Group. Immune checkpoint inhibitor–induced arthralgia is tightly associated with improved overall survival in cancer patients. Rheumatology, 2022;. keac519. doi : 10.1093/rheumatology/keac519 | Roche | 3 | |
| 7591, 7392 | Neeraj Narula | Hamilton Health Sciences | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease | Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug 24:S1542-3565(22)00811-4. doi : 10.1016/j.cgh.2022.08.015 | AbbVie, Johnson & Johnson, Pfizer, Takeda | 3 | |
| 7591, 7392 | Neeraj Narula | Hamilton Health Sciences | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease | Emily C L Wong, BHSc, Parambir S Dulai, MD, John K Marshall, MD, MSc, FRCPC, Vipul Jairath, MD, PhD, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH, FRCPC. Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease. Inflammatory Bowel Diseases. 2022. izac231. doi : 10.1093/ibd/izac231 | AbbVie, Takeda, Pfizer | 3 | |
| 7609 | Joao Pedro Ferreira | Porto University | The impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baseline | Ferreira JP, Sharma A, Vasques-Nóvoa F, Angélico-Gonçalves A, Leite AR, Borges-Canha M, Carvalho D, Packer M, Zannad F, Leite-Moreira A, Neves JS. Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes. Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2660 | GlaxoSmithKline | 6 | |
| 8342, 7444 | Gus Slotman | Inspira Health Network | IDENTIFYING TOCILIZUMAB-RESPONSIVE COVID-19 PATIENTS FROM COVACTA, EMPACTA, AND REMDACTA RANDOMIZED CLINICAL TRIAL PRE-RANDOMIZATION DATA | Kelter, D. and Slotman, G.J., 2022. Smart Identifies Dichotomous Drotrecogin Alfa Activated Treatment Effects on Mortality in Prowess Shock. Journal of the American College of Surgeons, 235(5), p.S296. Doi: 10.1097/01.XCS.0000895332.83940.b8 | Roche | N/A |
Center for Global Research Data